PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Acetylcysteine - Reduction of sputum viscosity
PAD Profile : Acetylcysteine - Reduction of sputum viscosity
Keywords :
excessive mucous production, mucolytics, COPD, Bronchiectasis
Brand Names Include :
NACSYS, A-CYS, AceCil, Acepiro
Traffic Light Status
Status 1 of 2.
Status :
Green (see narrative)
Important
Formulations :
- Effervescent tablets
Important Information :
Prescribe generically as 600mg effervescent tablets sugar free.
Do not use in patients with bronchospasm or history of asthma.
Do not use in fluid or sodium restricted patients.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Status 2 of 2.
Status :
Non Formulary
Important
Formulations :
- Capsules
- Granules
- Oral solution
- Powder
- Tablets
Important Information :
These are either unlicensed or are not considered cost-effective treatment options - see guidelines for recommended products.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee approved the Primary Care guidance for prescribing oral mucolytics.
Acetylcysteine should be prescribed generically.
Refer to the guidance for full details.
Associated BNF Codes
03. Respiratory System
03.07.00. Mucolytics